Immuneonco Biopharmaceuticals (shanghai) Inc.
Clinical trials sponsored by Immuneonco Biopharmaceuticals (shanghai) Inc., explained in plain language.
-
Double immune attack: new drug combo takes on advanced liver cancer
Disease control Not yet recruitingThis clinical trial is testing a combination of two experimental drugs, IMM2510 and IMM27M, in people with advanced hepatocellular carcinoma (a type of liver cancer) who have not yet received treatment for their advanced disease. The drugs are designed to help the immune system r…
Phase: PHASE2 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug aims to stop IgG4 disease relapses without Long-Term steroids
Disease control Not yet recruitingThis study tests a drug called IMM0306 in 125 people with IgG4-related disease, a condition where the immune system attacks organs causing swelling and damage. The goal is to see if IMM0306 can prevent disease flare-ups and allow patients to safely stop taking steroids. Participa…
Phase: PHASE2, PHASE3 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for lymphoma patients: experimental drug combo enters final trial phase
Disease control Not yet recruitingThis Phase 3 trial tests whether adding the experimental drug IMM0306 to standard lenalidomide can improve outcomes for people with follicular lymphoma that has returned or stopped responding to treatment. About 198 participants will be randomly assigned to receive either IMM0306…
Phase: PHASE3 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo aims to fight Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial is testing a combination of two experimental drugs, IMM2510 and IMM01, in about 104 people with advanced solid tumors that have already been treated. The goal is to find safe doses and see if the combination can shrink tumors. The study is not yet recruitin…
Phase: PHASE1, PHASE2 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Jun 26, 2026 15:39 UTC